{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:17:52Z","timestamp":1776439072836,"version":"3.51.2"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Tolmar, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Misconceptions about testosterone therapy are prevalent and there is an unmet need for a review of current literature that can be leveraged by physicians to deliver safe and effective care for men with hypogonadism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This review aims to address common misconceptions about testosterone therapy using current literature and synthesize practical guidance for clinicians with patients who are starting testosterone therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A literature search of PubMed, Embase, CINAHL was carried out to identify associations between testosterone therapy and prostate cancer, cardiovascular risk, and hepatic toxicity; definitions of hypogonadism; and practical guidance for clinician with patients starting testosterone therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There is no evidence to support the misconception that testosterone therapy leads to or promotes progression of prostate cancer, no evidence that testosterone therapy increases cardiovascular risk, no evidence that newer oral testosterone therapy formulations (eg, testosterone undecanoate) are associated with hepatic toxicity, and no consistent definition of hypogonadism among regulatory agencies and expert bodies. Clinicians should diagnose hypogonadism using testosterone concentrations and\/or symptoms of testosterone deficiency, help patients select a testosterone therapy formulation that best fits their needs and preferences (including considerations for dose adjustment), ensure appropriate laboratory monitoring before and during treatment, and assess how patients are feeling during treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Testosterone therapy is not associated with increased prostate cancer or increased cardiovascular risk, newer oral testosterone therapy formulations are not associated with hepatic toxicity, and a strict definition of hypogonadism is difficult because patient individualization is required. Each patient in real-world clinical practices has unique baseline characteristics and will likely respond differently to testosterone therapy. As the primary goal of testosterone therapy is to provide relief from symptoms of hypogonadism, physicians should work with their male patients to create a comprehensive treatment plan that suits the patient\u2019s specific needs and preferences.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sxmrev\/qeaf011","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:21:24Z","timestamp":1741130484000},"page":"373-380","source":"Crossref","is-referenced-by-count":2,"title":["Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care"],"prefix":"10.1093","volume":"13","author":[{"given":"Mohit","family":"Khera","sequence":"first","affiliation":[{"name":"Baylor College of Medicine , Houston, TX 77030 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Hotaling","sequence":"additional","affiliation":[{"name":"University of Utah , Salt Lake City, UT 84112 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Miner","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Center, Miriam Hospital , Providence, RI 02906 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"issue":"12","key":"2025081808541462700_ref1","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study","volume":"89","author":"Araujo","year":"2004","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"2025081808541462700_ref2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1210\/jc.2009-1796","article-title":"Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study","volume":"95","author":"Tajar","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025081808541462700_ref3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"2","key":"2025081808541462700_ref4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1743-6109.2012.02944.x","article-title":"The 20-year public health impact and direct cost of testosterone deficiency in U.S. men","volume":"10","author":"Moskovic","year":"2013","journal-title":"J Sex Med"},{"issue":"4_Part_1","key":"2025081808541462700_ref5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1743-6109.2007.00531.x","article-title":"The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact","volume":"4","author":"Maggi","year":"2007","journal-title":"J Sex Med"},{"issue":"15","key":"2025081808541462700_ref6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2025081808541462700_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48692","article-title":"Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Bhasin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2025081808541462700_ref8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/pcan.2013.60","article-title":"The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Cui","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"2025081808541462700_ref9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025081808541462700_ref10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/bju.15042","article-title":"Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy","volume":"126","author":"Ahlering","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"2025081808541462700_ref11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1743-6109.2009.01161.x","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera","year":"2009","journal-title":"J Sex Med"},{"issue":"1","key":"2025081808541462700_ref12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1464-410X.2008.07882.x","article-title":"Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations","volume":"103","author":"Morales","year":"2009","journal-title":"BJU Int"},{"issue":"1","key":"2025081808541462700_ref13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ijir.2012.29","article-title":"Testosterone replacement therapy in the setting of prostate cancer treated with radiation","volume":"25","author":"Pastuszak","year":"2013","journal-title":"Int J Impot Res"},{"issue":"3","key":"2025081808541462700_ref14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"2025081808541462700_ref15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jch.14297","article-title":"Effects of the oral testosterone undecanoate Kyzatrex\u2122 on ambulatory blood pressure in hypogonadal men","volume":"23","author":"White","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025081808541462700_ref16"},{"issue":"18","key":"2025081808541462700_ref17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1503\/cmaj.150033","article-title":"Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline","volume":"187","author":"Morales","year":"2015","journal-title":"CMAJ"},{"issue":"1","key":"2025081808541462700_ref18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eprac.2023.09.012","article-title":"Cardiovascular outcomes of Hypogonadal men receiving testosterone replacement therapy: a meta-analysis of randomized controlled trials","volume":"30","author":"Sood","year":"2024","journal-title":"Endocr Pract"},{"issue":"2","key":"2025081808541462700_ref19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.mayocp.2014.10.011","article-title":"Testosterone therapy and cardiovascular risk: advances and controversies","volume":"90","author":"Morgentaler","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2025081808541462700_ref20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7326\/M23-2781","article-title":"Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men: individual participant data meta-analyses","volume":"177","author":"Yeap","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025081808541462700_ref21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/CEOR.S285434","article-title":"Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: a narrative review","volume":"Volume 13","author":"Yeo","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"2025081808541462700_ref22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ajh\/hps056","article-title":"Plasma total testosterone and incident cardiovascular events in hypertensive patients","volume":"26","author":"Vlachopoulos","year":"2013","journal-title":"Am J Hypertens"},{"issue":"40","key":"2025081808541462700_ref23","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","article-title":"Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men","volume":"36","author":"Sharma","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"2025081808541462700_ref24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/JU.0000000000002928","article-title":"What is a normal testosterone level for young men? Rethinking the 300 ng\/dL Cutoff for testosterone deficiency in men 20-44 years old","volume":"208","author":"Zhu","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"2025081808541462700_ref25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5534\/wjmh.190043","article-title":"'Testosterone Boosting' supplements composition and claims are not supported by the academic literature","volume":"38","author":"Clemesha","year":"2020","journal-title":"World J Mens Health"},{"issue":"5","key":"2025081808541462700_ref26","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.5489\/cuaj.7252","article-title":"Canadian Urological Association guideline on testosterone deficiency in men: evidence-based Q&A","volume":"15","author":"Grober","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"2025081808541462700_ref27","volume-title":"Facts about Dietary Supplements","author":"FDA"},{"issue":"6","key":"2025081808541462700_ref28","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2025081808541462700_ref29","volume-title":"Hawke, Common Herbal Dietary Supplement\u2013Drug Interactions. American Family Physicians","author":"Gary"},{"issue":"4","key":"2025081808541462700_ref30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5489\/cuaj.880","article-title":"A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians","volume":"4","author":"Morales","year":"2010","journal-title":"Can Urol Assoc J"},{"issue":"8","key":"2025081808541462700_ref31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/hrt.2003.021121","article-title":"Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life","volume":"90","author":"Malkin","year":"2004","journal-title":"Heart"},{"key":"2025081808541462700_ref32","volume-title":"XYOSTED (Testosterone Enanthate) Injection, for Subcutaneous Use CIII [Prescribing Information]","year":"2023"},{"key":"2025081808541462700_ref33","volume-title":"TLANDO (Testosterone Undecanoate) Capsules, for Oral Use, CIII [Prescribing Information]","year":"2024"},{"issue":"6","key":"2025081808541462700_ref34","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025081808541462700_ref35","first-page":"427","article-title":"The benefits and risks of testosterone replacement therapy: a review","volume":"5","author":"Bassil","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"18","key":"2025081808541462700_ref36","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16183261","article-title":"Sex, energy, well-being and low testosterone: an exploratory survey of U.S. Men's experiences on prescription testosterone","volume":"16","author":"Straftis","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"2025081808541462700_ref37","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1210\/jc.84.6.1966","article-title":"Effect of testosterone treatment on bone mineral density in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081808541462700_ref38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehi443","article-title":"Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial","volume":"27","author":"Malkin","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"2025081808541462700_ref39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.17925\/EE.2022.18.2.133","article-title":"Testosterone replacement therapy: a narrative review with a focus on new oral formulations","volume":"18","author":"Bhat","year":"2022","journal-title":"touchREV Endocrinol"},{"key":"2025081808541462700_ref40","volume-title":"Testosterone Replacement Therapy (TRT): What to Know","author":"Tee-Melegrito"},{"key":"2025081808541462700_ref41"},{"key":"2025081808541462700_ref42"},{"issue":"11","key":"2025081808541462700_ref43","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jsxm.2022.03.609","article-title":"Practice comparison and cost analysis of direct-to-consumer telemedicine platforms offering testosterone therapy","volume":"19","author":"Jesse","year":"2022","journal-title":"J Sex Med"},{"issue":"8","key":"2025081808541462700_ref44","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jsm.12951","article-title":"Perspective: regulatory Agencies' changes to testosterone product Labeling","volume":"12","author":"Corona","year":"2015","journal-title":"J Sex Med"},{"issue":"3","key":"2025081808541462700_ref45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5534\/wjmh.221027","article-title":"The British Society for Sexual Medicine Guidelines on male adult testosterone deficiency, with statements for practice","volume":"41","author":"Hackett","year":"2023","journal-title":"World J Mens Health"},{"issue":"6","key":"2025081808541462700_ref46","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jsxm.2022.03.611","article-title":"Testosterone therapy is associated with depression, suicidality, and intentional self-harm: analysis of a National Federated Database","volume":"19","author":"Nackeeran","year":"2022","journal-title":"J Sex Med"},{"key":"2025081808541462700_ref47","volume-title":"AVEED (Testosterone Undecanoate) Injection, for Intramuscular Use [Prescribing Information]","year":"2021"},{"issue":"3","key":"2025081808541462700_ref48","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2003-031467","article-title":"Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels","volume":"89","author":"Leder","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025081808541462700_ref49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-2265.2008.03327.x","article-title":"Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Burnett-Bowie","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2025081808541462700_ref50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1590\/s1677-5538.ibju.2019.0132","article-title":"Human chorionic gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone &gt; 300 ng\/dL","volume":"45","author":"Madhusoodanan","year":"2019","journal-title":"Int Braz J Urol"},{"issue":"1","key":"2025081808541462700_ref51","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.12788\/jfp.0342","article-title":"Are SERMs safe and effective for the treatment of hypogonadism in men?","volume":"71","author":"Joseph","year":"2022","journal-title":"J Fam Pract"},{"issue":"3","key":"2025081808541462700_ref52","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1002\/edm2.416","article-title":"Clomiphene citrate: a potential alternative for testosterone therapy in hypogonadal males","volume":"6","author":"Huijben","year":"2023","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"2025081808541462700_ref53","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/iju.IJU_372_16","article-title":"Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men","volume":"33","author":"Dadhich","year":"2017","journal-title":"Indian J Urol"},{"issue":"4","key":"2025081808541462700_ref54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1210\/endrev\/bnab001","article-title":"Androgen misuse and abuse","volume":"42","author":"Handelsman","year":"2021","journal-title":"Endocr Rev"},{"key":"2025081808541462700_ref55","volume-title":"FDA Approves New Changes to Testosterone Labeling Regarding the Risks Associated with Abuse and Dependence of Testosterone and Other Anabolic Androgenic Steroids (AAS)","author":"FDA"},{"key":"2025081808541462700_ref56","volume-title":"Stat Pearls","author":"Preuss","year":"2024"},{"issue":"6_suppl","key":"2025081808541462700_ref57","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1177\/036354659602406S14","article-title":"Intervention and prevention of steroid use in adolescents","volume":"24","author":"Elliot","year":"1996","journal-title":"Am J Sports Med"},{"issue":"3","key":"2025081808541462700_ref58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1542\/peds.87.3.283","article-title":"Anabolic steroid education and adolescents: do scare tactics work?","volume":"87","author":"Goldberg","year":"1991","journal-title":"Pediatrics"},{"issue":"1","key":"2025081808541462700_ref59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.13589","article-title":"The state of testosterone therapy since the FDA's 2015 labelling changes: indications and cardiovascular risk","volume":"89","author":"Miner","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"12","key":"2025081808541462700_ref60","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.jsxm.2022.09.002","article-title":"Two-year analysis of a new oral testosterone Undecanoate (TU) formulation in Hypogonadal men: efficacy, impact on psychosexual function, and safety","volume":"19","author":"Honig","year":"2022","journal-title":"J Sex Med"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/13\/3\/373\/62811132\/qeaf011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/13\/3\/373\/62811132\/qeaf011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T12:54:20Z","timestamp":1755521660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smr\/article\/13\/3\/373\/8100477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,30]]},"published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/sxmrev\/qeaf011","relation":{},"ISSN":["2050-0513","2050-0521"],"issn-type":[{"value":"2050-0513","type":"print"},{"value":"2050-0521","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,30]]}}}